What question did this study set out to answer?

To evaluate how transcutaneous neuromodulation affects fecal microbiota and serotonin levels in patients with functional constipation.

January 25, 2026Open Access

Influences of transcutaneous neuromodulation on fecal microbiota and short chain fatty acids in patients with functional constipation

Key Points

To evaluate how transcutaneous neuromodulation affects fecal microbiota and serotonin levels in patients with functional constipation.
Administered transcutaneous neuromodulation treatment to patients with functional constipation
Measured plasma serotonin levels and changes in fecal microbiota composition
Correlated serotonin changes with specific gut bacteria dynamics
Reported significant improvement in constipation symptoms following treatment
Increased plasma serotonin levels post-treatment
Observed changes in Blautia bacteria linked to serotonin fluctuations after neuromodulation

Abstract

TN treatment significantly improved the symptoms of FC patients and increased their plasma 5-HT expression levels. The correlation between 5-HT and Blautia-serotonin (which changed after TN treatment) indicated that the 5-HT changes caused by TN treatment might have a potential interaction with the dynamic changes of the intestinal microbiota.

Influences of transcutaneous neuromodulation on fecal microbiota and short chain fatty acids in patients with functional constipation

Key Points

Abstract

Cite This Study